The in-vivo prime editing platform market size has grown exponentially in recent years. It will grow from $1.26 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 29.4%. The growth in the historic period can be attributed to discovery of CRISPR technologies, growth of genetic disorder research, increased biotech funding, academic genome editing research, early success of gene therapies.
The in-vivo prime editing platform market size is expected to see exponential growth in the next few years. It will grow to $4.52 billion in 2030 at a compound annual growth rate (CAGR) of 29.1%. The growth in the forecast period can be attributed to clinical translation of prime editing, expansion of in-vivo gene therapies, regulatory support for genetic treatments, partnerships between biotech and pharma, innovation in delivery vectors. Major trends in the forecast period include advancement in precision genome editing, expansion of gene therapy research, growing focus on rare disease treatment, development of improved delivery systems, increased preclinical and clinical studies.
The growing demand for precise and efficient genome-editing solutions is expected to drive the expansion of the in-vivo prime editing platform market. Genome editing involves making accurate, targeted changes to DNA - the molecule that carries genetic information - while minimizing unintended edits and potential side effects. This demand is largely driven by the increasing need for targeted therapies that reduce errors and provide lasting clinical benefits. In-vivo prime editing platforms address this need by enabling highly accurate, targeted DNA corrections within living tissues, with minimal off-target effects and the potential for long-term therapeutic benefits. For instance, the World Economic Forum reported that over 2,000 gene therapies were in development worldwide, double the number from just three years ago. As a result, the rising demand for precise and efficient genome-editing solutions is contributing to the growth of the in-vivo prime editing platform market.
Companies in the in-vivo prime editing platform market are focusing on innovations in delivery systems to improve the targeting and accessibility of in-vivo therapies. Advanced delivery methods, such as lipid nanoparticles, viral vectors, and engineered extracellular vesicles, are crucial for encapsulating prime editing components such as Cas9 nickase, reverse transcriptase, and pegRNAs. These carriers protect the editing tools from degradation, facilitate efficient delivery into target cells, and improve tissue specificity. For example, in September 2023, Moderna, a US-based biotechnology company, demonstrated that optimized lipid nanoparticle formulations could deliver prime editing machinery to liver and muscle tissues in animal models with high precision. This allowed targeted genome modifications while minimizing off-target effects, showcasing how innovations in delivery systems are enhancing the precision and therapeutic potential of in-vivo prime editing therapies.
In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics, Inc. for an undisclosed sum. This acquisition aims to revolutionize the treatment of cardiovascular disease by developing one-time genetic therapies that provide lifelong cardiovascular risk reduction. Verve Therapeutics is a clinical-stage biotechnology company focused on using gene-editing technologies to develop genetic medicines for cardiovascular conditions.
Major companies operating in the in-vivo prime editing platform market are AstraZeneca PLC, Danaher Corporation, Regeneron Pharmaceuticals Inc., Moderna Inc., Integrated DNA Technologies Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Maravai LifeSciences Holdings Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Precision BioSciences Inc., Metagenomi Inc., Tessera Therapeutics Inc., Mammoth Biosciences Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc. (NTLA), Caribou Biosciences Inc., Scribe Therapeutics Inc., EGENESIS INC., Prime Medicine Inc., Cellectis S.A.
North America was the largest region in the in-vivo prime editing platform market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vivo prime editing platform market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vivo prime editing platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in-vivo prime editing platform market by increasing costs of specialized enzymes, reagents, delivery systems, and laboratory equipment. North America and Europe are affected due to dependence on Asia-Pacific suppliers. These costs raise R&D expenses for biotech firms. However, tariffs are encouraging domestic biomanufacturing, local reagent production, and strategic supply chain localization.
The in-vivo prime editing platform market research report is one of a series of new reports that provides in-vivo prime editing platform market statistics, including in-vivo prime editing platform industry global market size, regional shares, competitors with a in-vivo prime editing platform market share, detailed in-vivo prime editing platform market segments, market trends and opportunities, and any further data you may need to thrive in the in-vivo prime editing platform industry. This in-vivo prime editing platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The in-vivo prime editing platform is an advanced genome editing technology that allows precise, targeted DNA modifications directly within living organisms. It integrates a catalytically impaired CRISPR-Cas enzyme with a reverse transcriptase and employs a prime editing guide RNA (pegRNA) to introduce specific base changes, insertions, or deletions without causing double-strand breaks. This technique enables accurate correction of genetic mutations in tissues or organs, holding significant promise for therapeutic applications, particularly for inherited genetic disorders.
The primary product categories in the in-vivo prime editing platform include prime editing enzymes, guide RNAs (gRNAs), delivery systems, and related products. Prime editing enzymes are engineered proteins formed by fusing CRISPR-associated protein 9 nickase (Cas9 H840A) with reverse transcriptase (RT), typically derived from Moloney murine leukemia virus reverse transcriptase (M-MLV RT). In this system, the Cas9 nickase introduces a single-strand break in DNA, while the reverse transcriptase uses an RNA template to directly implement the intended modification. This allows precise search-and-replace genome editing without double-strand breaks, enhancing both safety and efficiency. Demand for prime editing enzymes is increasing alongside the advancement of clinical gene editing.
The in-vivo prime editing platform market consists of revenues earned by entities by providing services such as gene sequencing, genetic analysis, CRISPR -based editing, therapeutic development, preclinical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vivo prime editing platform market also includes sales of gene editing kits, reagents, enzymes, plasmids, delivery vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The in-vivo prime editing platform market size is expected to see exponential growth in the next few years. It will grow to $4.52 billion in 2030 at a compound annual growth rate (CAGR) of 29.1%. The growth in the forecast period can be attributed to clinical translation of prime editing, expansion of in-vivo gene therapies, regulatory support for genetic treatments, partnerships between biotech and pharma, innovation in delivery vectors. Major trends in the forecast period include advancement in precision genome editing, expansion of gene therapy research, growing focus on rare disease treatment, development of improved delivery systems, increased preclinical and clinical studies.
The growing demand for precise and efficient genome-editing solutions is expected to drive the expansion of the in-vivo prime editing platform market. Genome editing involves making accurate, targeted changes to DNA - the molecule that carries genetic information - while minimizing unintended edits and potential side effects. This demand is largely driven by the increasing need for targeted therapies that reduce errors and provide lasting clinical benefits. In-vivo prime editing platforms address this need by enabling highly accurate, targeted DNA corrections within living tissues, with minimal off-target effects and the potential for long-term therapeutic benefits. For instance, the World Economic Forum reported that over 2,000 gene therapies were in development worldwide, double the number from just three years ago. As a result, the rising demand for precise and efficient genome-editing solutions is contributing to the growth of the in-vivo prime editing platform market.
Companies in the in-vivo prime editing platform market are focusing on innovations in delivery systems to improve the targeting and accessibility of in-vivo therapies. Advanced delivery methods, such as lipid nanoparticles, viral vectors, and engineered extracellular vesicles, are crucial for encapsulating prime editing components such as Cas9 nickase, reverse transcriptase, and pegRNAs. These carriers protect the editing tools from degradation, facilitate efficient delivery into target cells, and improve tissue specificity. For example, in September 2023, Moderna, a US-based biotechnology company, demonstrated that optimized lipid nanoparticle formulations could deliver prime editing machinery to liver and muscle tissues in animal models with high precision. This allowed targeted genome modifications while minimizing off-target effects, showcasing how innovations in delivery systems are enhancing the precision and therapeutic potential of in-vivo prime editing therapies.
In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics, Inc. for an undisclosed sum. This acquisition aims to revolutionize the treatment of cardiovascular disease by developing one-time genetic therapies that provide lifelong cardiovascular risk reduction. Verve Therapeutics is a clinical-stage biotechnology company focused on using gene-editing technologies to develop genetic medicines for cardiovascular conditions.
Major companies operating in the in-vivo prime editing platform market are AstraZeneca PLC, Danaher Corporation, Regeneron Pharmaceuticals Inc., Moderna Inc., Integrated DNA Technologies Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Maravai LifeSciences Holdings Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Precision BioSciences Inc., Metagenomi Inc., Tessera Therapeutics Inc., Mammoth Biosciences Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc. (NTLA), Caribou Biosciences Inc., Scribe Therapeutics Inc., EGENESIS INC., Prime Medicine Inc., Cellectis S.A.
North America was the largest region in the in-vivo prime editing platform market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in-vivo prime editing platform market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in-vivo prime editing platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the in-vivo prime editing platform market by increasing costs of specialized enzymes, reagents, delivery systems, and laboratory equipment. North America and Europe are affected due to dependence on Asia-Pacific suppliers. These costs raise R&D expenses for biotech firms. However, tariffs are encouraging domestic biomanufacturing, local reagent production, and strategic supply chain localization.
The in-vivo prime editing platform market research report is one of a series of new reports that provides in-vivo prime editing platform market statistics, including in-vivo prime editing platform industry global market size, regional shares, competitors with a in-vivo prime editing platform market share, detailed in-vivo prime editing platform market segments, market trends and opportunities, and any further data you may need to thrive in the in-vivo prime editing platform industry. This in-vivo prime editing platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The in-vivo prime editing platform is an advanced genome editing technology that allows precise, targeted DNA modifications directly within living organisms. It integrates a catalytically impaired CRISPR-Cas enzyme with a reverse transcriptase and employs a prime editing guide RNA (pegRNA) to introduce specific base changes, insertions, or deletions without causing double-strand breaks. This technique enables accurate correction of genetic mutations in tissues or organs, holding significant promise for therapeutic applications, particularly for inherited genetic disorders.
The primary product categories in the in-vivo prime editing platform include prime editing enzymes, guide RNAs (gRNAs), delivery systems, and related products. Prime editing enzymes are engineered proteins formed by fusing CRISPR-associated protein 9 nickase (Cas9 H840A) with reverse transcriptase (RT), typically derived from Moloney murine leukemia virus reverse transcriptase (M-MLV RT). In this system, the Cas9 nickase introduces a single-strand break in DNA, while the reverse transcriptase uses an RNA template to directly implement the intended modification. This allows precise search-and-replace genome editing without double-strand breaks, enhancing both safety and efficiency. Demand for prime editing enzymes is increasing alongside the advancement of clinical gene editing.
The in-vivo prime editing platform market consists of revenues earned by entities by providing services such as gene sequencing, genetic analysis, CRISPR -based editing, therapeutic development, preclinical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vivo prime editing platform market also includes sales of gene editing kits, reagents, enzymes, plasmids, delivery vectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. in-Vivo Prime Editing Platform Market Characteristics
3. in-Vivo Prime Editing Platform Market Supply Chain Analysis
4. Global in-Vivo Prime Editing Platform Market Trends and Strategies
5. in-Vivo Prime Editing Platform Market Analysis of End Use Industries
7. Global in-Vivo Prime Editing Platform Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global in-Vivo Prime Editing Platform Total Addressable Market (TAM) Analysis for the Market
9. in-Vivo Prime Editing Platform Market Segmentation
10. in-Vivo Prime Editing Platform Market Regional and Country Analysis
11. Asia-Pacific in-Vivo Prime Editing Platform Market
12. China in-Vivo Prime Editing Platform Market
13. India in-Vivo Prime Editing Platform Market
14. Japan in-Vivo Prime Editing Platform Market
15. Australia in-Vivo Prime Editing Platform Market
16. Indonesia in-Vivo Prime Editing Platform Market
17. South Korea in-Vivo Prime Editing Platform Market
18. Taiwan in-Vivo Prime Editing Platform Market
19. South East Asia in-Vivo Prime Editing Platform Market
20. Western Europe in-Vivo Prime Editing Platform Market
21. UK in-Vivo Prime Editing Platform Market
22. Germany in-Vivo Prime Editing Platform Market
23. France in-Vivo Prime Editing Platform Market
24. Italy in-Vivo Prime Editing Platform Market
25. Spain in-Vivo Prime Editing Platform Market
26. Eastern Europe in-Vivo Prime Editing Platform Market
27. Russia in-Vivo Prime Editing Platform Market
28. North America in-Vivo Prime Editing Platform Market
29. USA in-Vivo Prime Editing Platform Market
30. Canada in-Vivo Prime Editing Platform Market
31. South America in-Vivo Prime Editing Platform Market
32. Brazil in-Vivo Prime Editing Platform Market
33. Middle East in-Vivo Prime Editing Platform Market
34. Africa in-Vivo Prime Editing Platform Market
36. in-Vivo Prime Editing Platform Market Competitive Landscape and Company Profiles
37. in-Vivo Prime Editing Platform Market Other Major and Innovative Companies
40. in-Vivo Prime Editing Platform Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
In-vivo Prime Editing Platform Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses in-vivo prime editing platform market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for in-vivo prime editing platform? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in-vivo prime editing platform market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Prime Editing Enzymes; Guide Ribonucleic Acids; Delivery Systems; Other Product Types2) By Application: Genetic Disease Treatment; Oncology; Rare Diseases; Research And Development
3) By Delivery Method: Viral Vectors; Non-Viral Methods; Lipid Nanoparticles; Other Delivery Method Types
4) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Other End-Users
Subsegments:
1) By Prime Editing Enzymes: Cas9 Nickeas; Reverse Transcriptase; Engineered Variants2) By Guide Ribonucleic Acids: pegRNA (Prime Editing Guide RNA); sgRNA (Single Guide RNA); Optimized Synthetic RNAs
3) By Delivery Systems: Viral Vectors (AAV, Lentivirus); Non-Viral Vectors (Lipid Nanoparticles, Electroporation, Physical Methods); Exosomes
4) By Other Product Types: Screening Tools; Assay Kits; Supporting Reagents
Companies Mentioned: AstraZeneca PLC; Danaher Corporation; Regeneron Pharmaceuticals Inc.; Moderna Inc.; Integrated DNA Technologies Inc.; Beam Therapeutics Inc.; CRISPR Therapeutics AG; Maravai LifeSciences Holdings Inc.; Sangamo Therapeutics Inc.; Editas Medicine Inc.; Precision BioSciences Inc.; Metagenomi Inc.; Tessera Therapeutics Inc.; Mammoth Biosciences Inc.; Arbor Biotechnologies Inc.; Intellia Therapeutics Inc. (NTLA); Caribou Biosciences Inc.; Scribe Therapeutics Inc.; EGENESIS INC.; Prime Medicine Inc.; Cellectis S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this In-vivo Prime Editing Platform market report include:- AstraZeneca PLC
- Danaher Corporation
- Regeneron Pharmaceuticals Inc.
- Moderna Inc.
- Integrated DNA Technologies Inc.
- Beam Therapeutics Inc.
- CRISPR Therapeutics AG
- Maravai LifeSciences Holdings Inc.
- Sangamo Therapeutics Inc.
- Editas Medicine Inc.
- Precision BioSciences Inc.
- Metagenomi Inc.
- Tessera Therapeutics Inc.
- Mammoth Biosciences Inc.
- Arbor Biotechnologies Inc.
- Intellia Therapeutics Inc. (NTLA)
- Caribou Biosciences Inc.
- Scribe Therapeutics Inc.
- EGENESIS INC.
- Prime Medicine Inc.
- Cellectis S.A.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.63 Billion |
| Forecasted Market Value ( USD | $ 4.52 Billion |
| Compound Annual Growth Rate | 29.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
